Acadia Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
18.28
+1.78 (10.79%)
At close: Nov 10, 2026, 4:00 PM EST
18.00
-0.28 (-1.53%)
After-hours: Nov 10, 2026, 7:30 PM EST
Acadia Pharmaceuticals Revenue
Acadia Pharmaceuticals had revenue of $342.29M in the quarter ending September 30, 2026, with 22.85% growth. This brings the company's total for the last twelve months to $1.20B, up 14.82% year-over-year. In the year 2025, Acadia Pharmaceuticals had annual revenue of $1.07B with 11.87% growth. That makes Acadia Pharmaceuticals the 6,868th largest company in the world by revenue and 1,673rd in the United States.
Revenue (ttm)
$1.20B
Revenue Growth
+14.82%
P/S Ratio
2.63
Revenue / Employee
$1,506,643
Employees
798
Market Cap
3.16B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.07B | 113.71M | 11.87% |
| Dec 31, 2024 | 957.80M | 231.36M | 31.85% |
| Dec 31, 2023 | 726.44M | 209.20M | 40.45% |
| Dec 31, 2022 | 517.24M | 33.09M | 6.83% |
| Dec 31, 2021 | 484.15M | 42.39M | 9.60% |
| Dec 31, 2020 | 441.76M | 102.68M | 30.28% |
| Dec 31, 2019 | 339.08M | 115.27M | 51.50% |
| Dec 31, 2018 | 223.81M | 98.91M | 79.19% |
| Dec 31, 2017 | 124.90M | 107.57M | 620.68% |
| Dec 31, 2016 | 17.33M | 17.27M | 28,311.48% |
| Dec 31, 2015 | 61.00K | -59.00K | -49.17% |
| Dec 31, 2014 | 120.00K | -1.03M | -89.52% |
| Dec 31, 2013 | 1.15M | -3.76M | -76.67% |
| Dec 31, 2012 | 4.91M | 2.84M | 137.40% |
| Dec 31, 2011 | 2.07M | -40.07M | -95.09% |
| Dec 31, 2010 | 42.14M | 35.74M | 558.46% |
| Dec 31, 2009 | 6.40M | 4.81M | 302.45% |
| Dec 31, 2008 | 1.59M | -5.97M | -78.95% |
| Dec 31, 2007 | 7.56M | -578.00K | -7.11% |
| Dec 31, 2006 | 8.13M | -2.82M | -25.77% |
| Dec 31, 2005 | 10.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 890.79M |
| ADMA Biologics | 519.15M |
| Zai Lab | 441.73M |
| Vericel | 324.17M |
| Xencor | 200.49M |
| Beam Therapeutics | 146.64M |
| Arcus Biosciences | 100.00M |
| IDEAYA Biosciences | 36.54M |
ACAD News
- 12 hours ago - Acadia Pharmaceuticals to present Remlifanserin data at CTAD - TheFly
- 12 hours ago - Acadia comments on federal court oral argument in Nuplazid patent appeal - TheFly
- 1 day ago - Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal - Business Wire
- 1 day ago - Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference - Business Wire
- 4 days ago - Acadia Pharmaceuticals price target raised to $38 from $36 at Canaccord - TheFly
- 6 days ago - Acadia Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts
- 6 days ago - Acadia Pharmaceuticals Earnings release: Q3 2026 - Filings
- 6 days ago - Acadia Pharmaceuticals Slides: Q3 2026 - Filings